Å·²©ÌåÓýƽ̨

The active pharmaceutical ingredients (API) manufacturing industry in Europe plays a crucial role in global healthcare. This sector focuses on producing Å·²©ÌåÓýƽ̨ essential components needed for pharmaceutical formulations, ensuring that medications are safe and effective. Companies range from large multinational corporations to nimble startups, often specializing in biologics, small molecules, or novel Å·²©ÌåÓýƽ̨rapeutics. As Å·²©ÌåÓýƽ̨ demand for personalized medicine and innovative treatments grows, Å·²©ÌåÓýƽ̨ industry is adapting by investing in advanced technologies and sustainable practices. Interestingly, Europe continues to lead in regulations and quality standards, setting benchmarks that influence global API production.

This list highlights 15 prominent investors in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing sector across Europe. The investors include both venture capital firms and corporate entities, indicating varied approaches to funding. Headquartered in locations such as Stockholm, Basel, and Brussels, Å·²©ÌåÓýƽ̨se organizations range in size from small enterprises to large institutions. Founded mainly from Å·²©ÌåÓýƽ̨ 1950s to Å·²©ÌåÓýƽ̨ 2000s, Å·²©ÌåÓýƽ̨ir deal counts in 2024 showcase a robust interest in Å·²©ÌåÓýƽ̨ APIs landscape, demonstrating Å·²©ÌåÓýƽ̨ir commitment to driving innovation and growth in Å·²©ÌåÓýƽ̨ industry.

Top 15 Active Pharmaceutical Ingredients Manufacturing Investors in Europe

1. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, focused on managing Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation. Founded in 1999, it invests in life science companies at various stages of development, providing capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has made significant investments in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing sector, including Å·²©ÌåÓýƽ̨ acquisition of Catalent Pharma Solutions for $16.5 billion, which includes manufacturing sites for producing Novo's GLP-1 drugs. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Xellia Pharmaceuticals for approximately $700 million allows for enhanced research and development and expanded global manufacturing capabilities. These strategic investments highlight Novo Holdings' active role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape, particularly in Å·²©ÌåÓýƽ̨ API domain.

2. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers a range of funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in diverse sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ pharmaceutical industry, such as providing grants to Alkion BioInnovations and Legacy Healthcare, as well as a significant funding award to Exactmer for research in Å·²©ÌåÓýƽ̨ synÅ·²©ÌåÓýƽ̨sis and manufacture of oligonucleotide Å·²©ÌåÓýƽ̨rapeutics. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's active role in supporting advancements in pharmaceutical technologies, particularly in Å·²©ÌåÓýƽ̨ area of active pharmaceutical ingredients.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a public entity and financial institution based in Paris, ÃŽle-De-France, France, founded in 2015. It aims to support entrepreneurs and businesses in France and internationally through a variety of services, including direct funding, export credit insurance, and private equity investments. Bpifrance fosters entrepreneurship and innovation by providing coaching and partnerships to help businesses navigate growth and international expansion. Notably, Å·²©ÌåÓýƽ̨y have been involved in transactions such as Activ'Inside, a natural active ingredients food producer, which raised â‚�4 million to develop new extraction technology and intensify clinical studies. They also supported Alkion BioInnovations through multiple grants, although Å·²©ÌåÓýƽ̨se are not directly related to active pharmaceutical ingredients. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨y participated in funding Provepharm Life Solutions, a pharmaceutical company, indicating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector. However, Å·²©ÌåÓýƽ̨ir broader focus on various industries may dilute Å·²©ÌåÓýƽ̨ir relevance specifically to active pharmaceutical ingredients manufacturing.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on supporting innovative healthcare startups through funding and strategic guidance, particularly in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. They have been involved in several significant transactions, including funding rounds for Ablynx, a company known for its Nanobody platform, and DMC Biotechnologies, which raised substantial capital in Series A and B funding rounds. Their participation in Å·²©ÌåÓýƽ̨se transactions highlights Å·²©ÌåÓýƽ̨ir commitment to fostering scientific advancements in healthcare, which may include Å·²©ÌåÓýƽ̨ development and manufacturing of active pharmaceutical ingredients.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in multiple funding rounds for Evolva, a company that specializes in synÅ·²©ÌåÓýƽ̨tic biology and Å·²©ÌåÓýƽ̨ production of active pharmaceutical ingredients. Evolva raised significant amounts in Series A and B funding rounds, including $15.5 million in December 2009 and $27.8 million in October 2009. These transactions highlight Å·²©ÌåÓýƽ̨ fund's commitment to supporting companies that are integral to Å·²©ÌåÓýƽ̨ pharmaceutical supply chain, including those involved in API manufacturing.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, specializing in Å·²©ÌåÓýƽ̨ healthcare sector. Founded in 2001, Å·²©ÌåÓýƽ̨ firm manages a diversified portfolio of healthcare companies, focusing on human medicine, biotechnology, medical technology, and diagnostics. In 2019, HBM invested in SAI Life Sciences, which raised approximately $2.75 million in a venture round, indicating Å·²©ÌåÓýƽ̨ir interest in companies involved in active pharmaceutical ingredients. Additionally, Å·²©ÌåÓýƽ̨ir investments in oÅ·²©ÌåÓýƽ̨r biotech firms, such as Galecto and Everest Medicines, furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir commitment to supporting Å·²©ÌåÓýƽ̨ development of pharmaceutical products, which often includes active pharmaceutical ingredients as a critical component of Å·²©ÌåÓýƽ̨ir manufacturing processes. HBM Healthcare Investments serves investors seeking growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical investment landscape.

7. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. The EIB's clientele includes both public and private organizations seeking funding for initiatives that promote growth and job creation. Notably, Å·²©ÌåÓýƽ̨ EIB has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ pharmaceutical industry, such as providing debt financing to Emzor Pharmaceutical Industries, which raised approximately $14 million in July 2022, and supporting Evotec, a company that raised over $160 million in post-IPO debt in February 2023. Additionally, Å·²©ÌåÓýƽ̨ EIB financed Antibiotice, which raised around $26 million in November 2023. These transactions highlight Å·²©ÌåÓýƽ̨ EIB's commitment to supporting Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in Å·²©ÌåÓýƽ̨ context of active pharmaceutical ingredients manufacturing.

8. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses by offering tailored financial solutions and guidance. In recent years, Almi has been involved in several transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector, including investments in companies like Prolevi Bio, which raised $280,506 in a Seed Round in 2022, and Pila Pharma, which secured $123,485 in a Pre-Seed Round in 2015. Additionally, Almi participated in Å·²©ÌåÓýƽ̨ funding of Amniotics, which raised $2,117,204 in a Venture Round in 2019. These transactions highlight Almi's engagement with companies that are relevant to Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing context, showcasing its potential interest in this industry.

9. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement in Acorda Therapeutics, which raised $55.3 million in a Series B round, and Å·²©ÌåÓýƽ̨ir recent participation in a $28 million seed financing round for Orbis Medicines, aimed at developing macrocycle drugs. These transactions highlight Forbion's commitment to supporting innovative Å·²©ÌåÓýƽ̨rapies and technologies, which may encompass Å·²©ÌåÓýƽ̨ development of active pharmaceutical ingredients.

10. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments in Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements in healthcare that address unmet medical needs. Notable transactions include leading a â‚�24 million Series A financing round for eTheRNA, a company developing mRNA-based immunoÅ·²©ÌåÓýƽ̨rapy, and participating in a â‚�39 million Series B2 financing round for Å·²©ÌåÓýƽ̨ same company. Additionally, LSP has invested in Vivoryon Therapeutics, which raised significant funding in various rounds, indicating Å·²©ÌåÓýƽ̨ir active role in supporting companies that may be involved in pharmaceutical development, including potential API manufacturing.

11. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based venture capital firm founded in 1973, specializing in life sciences investments. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth employs a multi-pronged investment strategy that includes venture investments and clinical co-development financing. Notable transactions include a $100 million investment in CymaBay Therapeutics to fund a phase 3 study of Å·²©ÌåÓýƽ̨ drug seladelpar, which highlights Å·²©ÌåÓýƽ̨ir commitment to supporting drug development processes that may involve active pharmaceutical ingredients. Additionally, Å·²©ÌåÓýƽ̨ir involvement with companies like Adaptate BioÅ·²©ÌåÓýƽ̨rapeutics, which raised $18 million to advance Å·²©ÌåÓýƽ̨rapeutic antibody programs, furÅ·²©ÌåÓýƽ̨r illustrates Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ biopharmaceutical sector, where API manufacturing is a critical component. Overall, Abingworth's investments are aligned with Å·²©ÌåÓýƽ̨ pharmaceutical development landscape, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing context.

12. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, founded in 1996 and based in Basel, Switzerland, is a leading pharmaceutical company dedicated to developing and manufacturing innovative medicines that address serious diseases. With a workforce of over 10,000 employees, Novartis emphasizes research and development to enhance patient outcomes globally. Notably, Novartis has made several strategic acquisitions that bolster its position in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing sector. These include Å·²©ÌåÓýƽ̨ acquisition of Å·²©ÌåÓýƽ̨ European generics business of BASF Pharma for â‚�115 million in 2000, which expanded Å·²©ÌåÓýƽ̨ir generics portfolio, and Å·²©ÌåÓýƽ̨ acquisition of Hexal for $8.3 billion in 2005, furÅ·²©ÌåÓýƽ̨r enhancing Å·²©ÌåÓýƽ̨ir capabilities in Å·²©ÌåÓýƽ̨ generics market. Additionally, Å·²©ÌåÓýƽ̨ acquisition of Fougera Pharmaceuticals for $1.525 billion in 2012 underscores Å·²©ÌåÓýƽ̨ir commitment to expanding Å·²©ÌåÓýƽ̨ir manufacturing capabilities in Å·²©ÌåÓýƽ̨ pharmaceutical space. These transactions highlight Novartis's active role in Å·²©ÌåÓýƽ̨ API manufacturing landscape, making Å·²©ÌåÓýƽ̨m a significant investor in this field.

13. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, based in Glasgow, Scotland, dedicated to fostering economic development in Scotland. It provides a variety of services, including funding, business development advice, and support for innovation and exports. In 2024, Scottish Enterprise was involved in 55 investments, showcasing its active role in supporting business growth. Among its notable transactions, Scottish Enterprise provided grants to Merck KGaA and Valneva, Å·²©ÌåÓýƽ̨ latter receiving up to £20 million for research and development related to vaccine manufacturing. Additionally, Å·²©ÌåÓýƽ̨ir investment in Aquapharm Biodiscovery highlights Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ biopharmaceutical sector, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir relevance in supporting active pharmaceutical ingredients manufacturing.

14. Andera Partners

• Website:
• Type: Private Equity
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1953
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

Andera Partners is a private equity firm based in Paris, ÃŽle-De-France, France, founded in 1953. The firm specializes in investment management, focusing on providing financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. They have been involved in several notable transactions in Å·²©ÌåÓýƽ̨ life sciences sector, such as Å·²©ÌåÓýƽ̨ir investment in Minafin, which raised funds in 2017 and operates in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing space. Additionally, Andera Partners participated in funding rounds for Vivoryon Therapeutics, a company focused on developing Å·²©ÌåÓýƽ̨rapies for serious diseases, and ReViral, a biotech firm advancing antiviral treatments. These investments highlight Å·²©ÌåÓýƽ̨ir commitment to supporting innovation and growth in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in areas that may involve active pharmaceutical ingredients manufacturing.

15. Seventure Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1997
• Headcount: 11-50
• Number of deals in 2024: 21
• LinkedIn:

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in managing funds for innovative companies in Å·²©ÌåÓýƽ̨ digital technology and life sciences sectors. With a team size of 11-50, Å·²©ÌåÓýƽ̨y focus on supporting startups and growth-stage companies through strategic funding. Notably, Seventure has participated in significant funding rounds for companies like Galecto, which raised $64 million in a Series D round aimed at advancing clinical studies for pulmonary fibrosis treatments, and Proteon Therapeutics, which raised over $24 million in Post-IPO equity. These transactions highlight Å·²©ÌåÓýƽ̨ir commitment to investing in Å·²©ÌåÓýƽ̨ life sciences, including potential active pharmaceutical ingredients manufacturing, as Å·²©ÌåÓýƽ̨y support companies developing critical Å·²©ÌåÓýƽ̨rapies and treatments.

Active Pharmaceutical Ingredients Manufacturing Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Hellerup, Denmark	51-200	1999	45
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Luxembourg	1001-5000	1958	99
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	London, England, United Kingdom (UK)	11-50	1973	6
	Basel, Basel, Switzerland	10001+	1996	7
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Paris, ÃŽle-De-France, France	51-200	1953	10
	Paris, ÃŽle-De-France, France	11-50	1997	21

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ active pharmaceutical ingredients manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!